Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Alphamab Oncology's operating assets for the quarter that ended in Dec. 2025 was HK$825.0 Mil. Alphamab Oncology's operating liabilities for the quarter that ended in Dec. 2025 was HK$290.8 Mil. Alphamab Oncology's Total Assets for the quarter that ended in Jun. 2025 was HK$2,578.4 Mil. Therefore, Alphamab Oncology's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.21.
Alphamab Oncology Scaled Net Operating Assets Related Terms
Alphamab Oncology Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology Scaled Net Operating Assets Chart
HKSE:09966 vs VRTX, REGN, RVMD: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Alphamab Oncology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.21 mean?
Alphamab Oncology (HKSE:09966) has a Scaled Net Operating Assets of 0.21 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Scaled Net Operating Assets too high?
Alphamab Oncology's current Scaled Net Operating Assets is 0.21. Overall, Alphamab Oncology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Scaled Net Operating Assets compare to VRTX and REGN?
Alphamab Oncology's Scaled Net Operating Assets of 0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Scaled Net Operating Assets is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (HKSE:09966) is currently considered Fairly Valued. The stock's GF Value™ is HK$7.81, compared to a current price of HK$8.35 — trading 6.9% above its estimated fair value. The current Scaled Net Operating Assets is 0.21. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Alphamab Oncology (HKSE:09966), the current Scaled Net Operating Assets is 0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (HKSE:09966) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of HK$8.35 is trading 6.9% above its estimated GF Value™ of HK$7.81.
GuruFocus considers Alphamab Oncology to be Fairly Valued.
Key valuation signals for HKSE:09966:
Scaled Net Operating Assets: 0.21
GF Value™: HK$7.81 vs. price of HK$8.35 (6.9% above fair value)
No single metric tells the full story. See the HKSE:09966 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for HKSE:09966
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09966 has been successfully added to your 
